These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 8752839

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Randomized comparison of the type 4 phosphodiesterase inhibitor cipamfylline cream, cream vehicle and hydrocortisone 17-butyrate cream for the treatment of atopic dermatitis.
    Griffiths CE, Van Leent EJ, Gilbert M, Traulsen J, Cipamyflline Study Group.
    Br J Dermatol; 2002 Aug; 147(2):299-307. PubMed ID: 12174103
    [Abstract] [Full Text] [Related]

  • 3. Increased interleukin-4 production by atopic mononuclear leukocytes correlates with increased cyclic adenosine monophosphate-phosphodiesterase activity and is reversible by phosphodiesterase inhibition.
    Chan SC, Li SH, Hanifin JM.
    J Invest Dermatol; 1993 May; 100(5):681-4. PubMed ID: 8388009
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Monocyte phosphodiesterase abnormalities and dysregulation of lymphocyte function in atopic dermatitis.
    Hanifin JM, Chan SC.
    J Invest Dermatol; 1995 Jul; 105(1 Suppl):84S-88S. PubMed ID: 7616004
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Impaired lymphocyte cyclic adenosine monophosphate responses in atopic eczema.
    Archer CB, Morley J, MacDonald DM.
    Br J Dermatol; 1983 Nov; 109(5):559-64. PubMed ID: 6315045
    [Abstract] [Full Text] [Related]

  • 9. Increased leukocyte sensitivity to phosphodiesterase inhibitors in atopic dermatitis: tachyphylaxis after theophylline therapy.
    Giustina TA, Chan SC, Thiel ML, Baker JW, Hanifin JM.
    J Allergy Clin Immunol; 1984 Sep; 74(3 Pt 1):252-7. PubMed ID: 6088608
    [Abstract] [Full Text] [Related]

  • 10. Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model.
    Ishii N, Shirato M, Wakita H, Miyazaki K, Takase Y, Asano O, Kusano K, Yamamoto E, Inoue C, Hishinuma I.
    J Pharmacol Exp Ther; 2013 Jul; 346(1):105-12. PubMed ID: 23674603
    [Abstract] [Full Text] [Related]

  • 11. A murine model of epicutaneous protein sensitization is useful to study efficacies of topical drugs in atopic dermatitis.
    Lehto M, Savinko T, Wolff H, Kvist PH, Kemp K, Lauerma A, Alenius H.
    Int Immunopharmacol; 2010 Apr; 10(4):377-84. PubMed ID: 20074670
    [Abstract] [Full Text] [Related]

  • 12. Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic Dermatitis.
    Jarnagin K, Chanda S, Coronado D, Ciaravino V, Zane LT, Guttman-Yassky E, Lebwohl MG.
    J Drugs Dermatol; 2016 Apr; 15(4):390-6. PubMed ID: 27050693
    [Abstract] [Full Text] [Related]

  • 13. gamma-interferon production in atopic dermatitis shows differential modification by phosphodiesterase and prostaglandin inhibition.
    Ostlere LS, Mallett RB, Kaminski A, Kaminski ER, Pereira RS, Holden CA.
    Br J Dermatol; 1995 Jul; 133(1):1-5. PubMed ID: 7669618
    [Abstract] [Full Text] [Related]

  • 14. Phosphodiesterase inhibitors suppress proliferation of peripheral blood mononuclear cells and interleukin-4 and -5 secretion by human T-helper type 2 cells.
    Crocker IC, Townley RG, Khan MM.
    Immunopharmacology; 1996 Mar; 31(2-3):223-35. PubMed ID: 8861748
    [Abstract] [Full Text] [Related]

  • 15. OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study.
    Hanifin JM, Ellis CN, Frieden IJ, Fölster-Holst R, Stein Gold LF, Secci A, Smith AJ, Zhao C, Kornyeyeva E, Eichenfield LF.
    J Am Acad Dermatol; 2016 Aug; 75(2):297-305. PubMed ID: 27189825
    [Abstract] [Full Text] [Related]

  • 16. ME3183, a novel phosphodiesterase-4 inhibitor, exhibits potent anti-inflammatory effects and is well tolerated in a non-clinical study.
    Kubota-Ishida N, Kaji C, Matsumoto S, Wakabayashi T, Matsuhira T, Okura I, Cho N, Isshiki S, Kumura K, Tabata Y.
    Eur J Pharmacol; 2024 Jan 05; 962():176202. PubMed ID: 37996010
    [Abstract] [Full Text] [Related]

  • 17. Adrenoceptor function in atopic dermatitis: in vitro and in vivo observations.
    Archer CB, Hanson JM, Morley J, MacDonald DM.
    Acta Derm Venereol Suppl (Stockh); 1985 Jan 05; 114():93-7. PubMed ID: 2860767
    [Abstract] [Full Text] [Related]

  • 18. Increased leukocyte histamine release with elevated cyclic AMP-phosphodiesterase activity in atopic dermatitis.
    Butler JM, Chan SC, Stevens S, Hanifin JM.
    J Allergy Clin Immunol; 1983 May 05; 71(5):490-7. PubMed ID: 6188771
    [Abstract] [Full Text] [Related]

  • 19. Crisaborole: Phosphodiesterase inhibitor for treatment of atopic dermatitis.
    Paton DM.
    Drugs Today (Barc); 2017 Apr 05; 53(4):239-245. PubMed ID: 28492291
    [Abstract] [Full Text] [Related]

  • 20. [Clinical trials in dermatology. Evaluation of the tolerability and efficacy of a topical anti-inflammatory treatment in atopic dermatitis].
    Queille-Roussel C, Dahan C, Poncet M, Schaefer H, Revuz J, De Prost Y, Guillaume JC, Ortonne JP, Czernielewski J.
    Therapie; 1991 Apr 05; 46(3):193-6. PubMed ID: 1792650
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.